Protein / target
Nicotinamide phosphoribosyltransferase
Protein at a glance
Biological role
Nicotinamide phosphoribosyltransferase
Strongest disease association
Eosinophilic Esophagitis
Therapeutic position
Clinically advancing target
Research activity
Emerging research
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD.
View complete UniProt function annotationHide complete annotation
Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack of activation by ATP, which has a low level in extracellular space and plasma. Plays a role in the modulation of circadian clock function. NAMPT-dependent oscillatory production of NAD regulates oscillation of clock target gene expression by releasing the core clock component: CLOCK-BMAL1 heterodimer from NAD-dependent SIRT1-mediated suppression (By similarity)
Subcellular location
Domains and Gene Ontology detail (20)Hide
Gene Ontology
- Ccytosol
- Cextracellular exosome
- Cmitochondrial matrix
- Cnucleus
- Fcytokine activity
- Fidentical protein binding
- Fnicotinamide phosphoribosyltransferase activity
- Pcell-cell signaling
- Pcircadian regulation of gene expression
- Pinflammatory response
- PNAD+ biosynthetic process
- PNAD+ biosynthetic process via the salvage pathway
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell proliferation & survival
- ·positive regulation of cell population proliferation
Transcriptional regulation
- ·Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yiel…
- ·circadian regulation of gene expression
- ·positive regulation of gene expression
- ·positive regulation of transcription by RNA polymerase II
Immune signalling
- ·Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yiel…
- ·cytokine activity
- ·inflammatory response
Metabolic enzyme activity
- ·nicotinamide phosphoribosyltransferase activity
- ·nicotinate metabolic process
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene NAMPT
Gene-level evidence surfaced through the gene NAMPTthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
3 compounds recorded · 3 in clinical development
View all recorded compounds (3)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
View underlying tractability evidence (10)Hide
Raw Open Targets tractability assessment buckets, by modality.
Research activity
Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.
Most cited
Recent
Europe PMC papers linked directly to this protein.